The corporate venturing unit of life sciences company Eli Lilly and chemicals group BASF, could realise its investment in Receptos, a US-based therapeutics company planning its flotation. Receptos has filed for an $86.3m initial public offering on the Nasdaq stock exchange. Investment banks Credit Suisse, Leerink Swann and BMO Capital Markets are lead underwriters.   To date, Receptos has raised close to $75m from investors, including BASF’s corporate venturing unit (15.7% pre-IPO stake) and Lilly Ventures (15.6%) and venture capital firms Arch Venture Partners, Venrock Associates (14.6%), Flagship Ventures (14.6%) and Polaris Venture Partners (8.3%). Receptos’ latest financial reports state a $17.6m net loss on about $8.6m in revenues for 2012. 

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?